Novartis may be looking at another trial of its troubled blood pressure drug Tekturna. This would not be a clinical trial, however, but more of the civil or criminal kind.
As anyone in pharma knows, data can be a wonderful thing. Crunching data can also be addictive, like kettle corn or tortilla chips. We here at FierceMarkets can spend hours consuming statistics about our readers and web traffic. Here are the stories that garnered the most web traffic over the past 12 months. More >>
The data on Rasilez 's safety risks is coming home to roost. The Novartis ($NVS) blood-pressure drug will get a new warning in Europe at regulators' request, after a recent trial flagged links...
Bad news for Novartis' ($NVS) blood pressure med Tekturna (aka Rasilez). The drug company has decided to end a trial evaluating the med in Type 2 diabetes patients with renal impairment who are also
Novartis' ($NVS) bid to expand the use of Rasilez has run into serious trouble. The pharma company joined the lineup of Big Pharma companies reporting trial setbacks today with the news that
Swiss drug giant Novartis ($NVS) revealed Monday that it has a green light to market a combo pill in the European Union to patients who need multiple meds to control their high blood pressure. The
Bolstered by the EU's blessing on its new hypertension treatment Rasilez, Novartis is planning a â‚¬183 million ($250 million) expansion of a plant near Basel, Switzerland. The expansion will boost